Review





Similar Products

mdm2 mutant  (Genecopoeia)
94
Genecopoeia mdm2 mutant
Mdm2 Mutant, supplied by Genecopoeia, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mutant+mdm2/pm41882000-334-21-17?v=Genecopoeia
Average 94 stars, based on 1 article reviews
mdm2 mutant - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier
mutant mdm2 dehd complexes  (Molecular Dynamics Inc)
86
Molecular Dynamics Inc mutant mdm2 dehd complexes
Mutant Mdm2 Dehd Complexes, supplied by Molecular Dynamics Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mutant+mdm2/pm41390711-163-21-28?v=Molecular+Dynamics+Inc
Average 86 stars, based on 1 article reviews
mutant mdm2 dehd complexes - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier
mutant mt mdm2 primers  (Sangon Biotech)
86
Sangon Biotech mutant mt mdm2 primers
Mutant Mt Mdm2 Primers, supplied by Sangon Biotech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mutant+mdm2/10__1515_slash_tjb___2024___0279-73-22-34?v=Sangon+Biotech
Average 86 stars, based on 1 article reviews
mutant mt mdm2 primers - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier
pcmv mdm2 c464a mutant  (Addgene inc)
93
Addgene inc pcmv mdm2 c464a mutant
A The frequency of p53 mutation in Diffuse Large B Cell lymphoma (DLBC) patients (DFCI, Nat Med, 2018 ), (Broad, PNAS, 2012), (BCGSC, Blood, 2013 ), (TCGA, PanCancer Atlas), (Duke, Cell, 2017) , ALL patients (St Jude, Nat Genet, 2016), (St Jude, Nat Genet, 2015) , and pediatric ALL patients (TARGET, 2018)—across public datasets in https://www.cbioportal.org . B U2OS cells were transfected with an empty or FLT4 expression plasmid along with a pg13 luciferase reporter vector or a luciferase reporter for p21 or MDM2 to determine p53 target genes activity. C U2OS cells were transfected with an empty or FLT4 expression vector for 24 h. The cells were then treated with 10 µg/mL of 5-FU for 6 h. The cell lysates were blotted for the indicated antibodies. D U2OS cells were transfected with different combinations of FLT4, MDM2, and MDMX plasmids along with pg13 luciferase reporter vector to determine endogenous p53 under genotoxic conditions with 5-FU. E HEK293T cells were transfected with various amounts of FLT4 expression plasmid for 24 h. The cell lysates were blotted for the indicated antibodies. F HEK293T cells were transfected with a combination of FLT4, MDMX and MDM2 expression plasmids for 24 h. The cell lysates were blotted for the indicated antibodies (LE low exposure, HE high exposure). G U2OS cells were transfected with a combination of FLT4, MDMX or MDM2 expression plasmids for 24 h. The cell lysates were blotted for the indicated antibodies. H U2OS cells were transfected with a combination of FLT4, MDMX, wild-type MDM2 or mutant MDM2 <t>C464A</t> expression plasmids for 24 h. The cell lysates were blotted for the indicated antibodies. I U2OS cells were transfected with a combination of FLT4, MDMX, and MDM2 expression plasmids and immunostained for MDMX (green) and MDM2 (red), while the nuclei were stained with Hoechst. Scale bar: 20 μm. * p < 0.05, **** p < 0.0001.
Pcmv Mdm2 C464a Mutant, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mutant+mdm2/pmc12048674-41-4-13?v=Addgene+inc
Average 93 stars, based on 1 article reviews
pcmv mdm2 c464a mutant - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier
pcmv-mdm2 c464a mutant  (Addgene inc)
90
Addgene inc pcmv-mdm2 c464a mutant
A The frequency of p53 mutation in Diffuse Large B Cell lymphoma (DLBC) patients (DFCI, Nat Med, 2018 ), (Broad, PNAS, 2012), (BCGSC, Blood, 2013 ), (TCGA, PanCancer Atlas), (Duke, Cell, 2017) , ALL patients (St Jude, Nat Genet, 2016), (St Jude, Nat Genet, 2015) , and pediatric ALL patients (TARGET, 2018)—across public datasets in https://www.cbioportal.org . B U2OS cells were transfected with an empty or FLT4 expression plasmid along with a pg13 luciferase reporter vector or a luciferase reporter for p21 or MDM2 to determine p53 target genes activity. C U2OS cells were transfected with an empty or FLT4 expression vector for 24 h. The cells were then treated with 10 µg/mL of 5-FU for 6 h. The cell lysates were blotted for the indicated antibodies. D U2OS cells were transfected with different combinations of FLT4, MDM2, and MDMX plasmids along with pg13 luciferase reporter vector to determine endogenous p53 under genotoxic conditions with 5-FU. E HEK293T cells were transfected with various amounts of FLT4 expression plasmid for 24 h. The cell lysates were blotted for the indicated antibodies. F HEK293T cells were transfected with a combination of FLT4, MDMX and MDM2 expression plasmids for 24 h. The cell lysates were blotted for the indicated antibodies (LE low exposure, HE high exposure). G U2OS cells were transfected with a combination of FLT4, MDMX or MDM2 expression plasmids for 24 h. The cell lysates were blotted for the indicated antibodies. H U2OS cells were transfected with a combination of FLT4, MDMX, wild-type MDM2 or mutant MDM2 <t>C464A</t> expression plasmids for 24 h. The cell lysates were blotted for the indicated antibodies. I U2OS cells were transfected with a combination of FLT4, MDMX, and MDM2 expression plasmids and immunostained for MDMX (green) and MDM2 (red), while the nuclei were stained with Hoechst. Scale bar: 20 μm. * p < 0.05, **** p < 0.0001.
Pcmv Mdm2 C464a Mutant, supplied by Addgene inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mutant+mdm2/pm40316529-57-3-13?v=Addgene+inc
Average 90 stars, based on 1 article reviews
pcmv-mdm2 c464a mutant - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
mutant promoter plasmid (plg3b-mdm2-mut)  (Obio Technology Corp Ltd)
90
Obio Technology Corp Ltd mutant promoter plasmid (plg3b-mdm2-mut)
A The frequency of p53 mutation in Diffuse Large B Cell lymphoma (DLBC) patients (DFCI, Nat Med, 2018 ), (Broad, PNAS, 2012), (BCGSC, Blood, 2013 ), (TCGA, PanCancer Atlas), (Duke, Cell, 2017) , ALL patients (St Jude, Nat Genet, 2016), (St Jude, Nat Genet, 2015) , and pediatric ALL patients (TARGET, 2018)—across public datasets in https://www.cbioportal.org . B U2OS cells were transfected with an empty or FLT4 expression plasmid along with a pg13 luciferase reporter vector or a luciferase reporter for p21 or MDM2 to determine p53 target genes activity. C U2OS cells were transfected with an empty or FLT4 expression vector for 24 h. The cells were then treated with 10 µg/mL of 5-FU for 6 h. The cell lysates were blotted for the indicated antibodies. D U2OS cells were transfected with different combinations of FLT4, MDM2, and MDMX plasmids along with pg13 luciferase reporter vector to determine endogenous p53 under genotoxic conditions with 5-FU. E HEK293T cells were transfected with various amounts of FLT4 expression plasmid for 24 h. The cell lysates were blotted for the indicated antibodies. F HEK293T cells were transfected with a combination of FLT4, MDMX and MDM2 expression plasmids for 24 h. The cell lysates were blotted for the indicated antibodies (LE low exposure, HE high exposure). G U2OS cells were transfected with a combination of FLT4, MDMX or MDM2 expression plasmids for 24 h. The cell lysates were blotted for the indicated antibodies. H U2OS cells were transfected with a combination of FLT4, MDMX, wild-type MDM2 or mutant MDM2 <t>C464A</t> expression plasmids for 24 h. The cell lysates were blotted for the indicated antibodies. I U2OS cells were transfected with a combination of FLT4, MDMX, and MDM2 expression plasmids and immunostained for MDMX (green) and MDM2 (red), while the nuclei were stained with Hoechst. Scale bar: 20 μm. * p < 0.05, **** p < 0.0001.
Mutant Promoter Plasmid (Plg3b Mdm2 Mut), supplied by Obio Technology Corp Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mutant+mdm2/10__1016_slash_j__ijbiomac__2024__137457-51-23-30?v=Obio+Technology+Corp+Ltd
Average 90 stars, based on 1 article reviews
mutant promoter plasmid (plg3b-mdm2-mut) - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
147 pcmv mdm2 c464a mutant  (Addgene inc)
93
Addgene inc 147 pcmv mdm2 c464a mutant
A The frequency of p53 mutation in Diffuse Large B Cell lymphoma (DLBC) patients (DFCI, Nat Med, 2018 ), (Broad, PNAS, 2012), (BCGSC, Blood, 2013 ), (TCGA, PanCancer Atlas), (Duke, Cell, 2017) , ALL patients (St Jude, Nat Genet, 2016), (St Jude, Nat Genet, 2015) , and pediatric ALL patients (TARGET, 2018)—across public datasets in https://www.cbioportal.org . B U2OS cells were transfected with an empty or FLT4 expression plasmid along with a pg13 luciferase reporter vector or a luciferase reporter for p21 or MDM2 to determine p53 target genes activity. C U2OS cells were transfected with an empty or FLT4 expression vector for 24 h. The cells were then treated with 10 µg/mL of 5-FU for 6 h. The cell lysates were blotted for the indicated antibodies. D U2OS cells were transfected with different combinations of FLT4, MDM2, and MDMX plasmids along with pg13 luciferase reporter vector to determine endogenous p53 under genotoxic conditions with 5-FU. E HEK293T cells were transfected with various amounts of FLT4 expression plasmid for 24 h. The cell lysates were blotted for the indicated antibodies. F HEK293T cells were transfected with a combination of FLT4, MDMX and MDM2 expression plasmids for 24 h. The cell lysates were blotted for the indicated antibodies (LE low exposure, HE high exposure). G U2OS cells were transfected with a combination of FLT4, MDMX or MDM2 expression plasmids for 24 h. The cell lysates were blotted for the indicated antibodies. H U2OS cells were transfected with a combination of FLT4, MDMX, wild-type MDM2 or mutant MDM2 <t>C464A</t> expression plasmids for 24 h. The cell lysates were blotted for the indicated antibodies. I U2OS cells were transfected with a combination of FLT4, MDMX, and MDM2 expression plasmids and immunostained for MDMX (green) and MDM2 (red), while the nuclei were stained with Hoechst. Scale bar: 20 μm. * p < 0.05, **** p < 0.0001.
147 Pcmv Mdm2 C464a Mutant, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mutant+mdm2/ppr0669787-46-4-13?v=Addgene+inc
Average 93 stars, based on 1 article reviews
147 pcmv mdm2 c464a mutant - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier
murine double mutant 2 mdm2 51541 antibodies  (Cell Signaling Technology Inc)
95
Cell Signaling Technology Inc murine double mutant 2 mdm2 51541 antibodies
A The frequency of p53 mutation in Diffuse Large B Cell lymphoma (DLBC) patients (DFCI, Nat Med, 2018 ), (Broad, PNAS, 2012), (BCGSC, Blood, 2013 ), (TCGA, PanCancer Atlas), (Duke, Cell, 2017) , ALL patients (St Jude, Nat Genet, 2016), (St Jude, Nat Genet, 2015) , and pediatric ALL patients (TARGET, 2018)—across public datasets in https://www.cbioportal.org . B U2OS cells were transfected with an empty or FLT4 expression plasmid along with a pg13 luciferase reporter vector or a luciferase reporter for p21 or MDM2 to determine p53 target genes activity. C U2OS cells were transfected with an empty or FLT4 expression vector for 24 h. The cells were then treated with 10 µg/mL of 5-FU for 6 h. The cell lysates were blotted for the indicated antibodies. D U2OS cells were transfected with different combinations of FLT4, MDM2, and MDMX plasmids along with pg13 luciferase reporter vector to determine endogenous p53 under genotoxic conditions with 5-FU. E HEK293T cells were transfected with various amounts of FLT4 expression plasmid for 24 h. The cell lysates were blotted for the indicated antibodies. F HEK293T cells were transfected with a combination of FLT4, MDMX and MDM2 expression plasmids for 24 h. The cell lysates were blotted for the indicated antibodies (LE low exposure, HE high exposure). G U2OS cells were transfected with a combination of FLT4, MDMX or MDM2 expression plasmids for 24 h. The cell lysates were blotted for the indicated antibodies. H U2OS cells were transfected with a combination of FLT4, MDMX, wild-type MDM2 or mutant MDM2 <t>C464A</t> expression plasmids for 24 h. The cell lysates were blotted for the indicated antibodies. I U2OS cells were transfected with a combination of FLT4, MDMX, and MDM2 expression plasmids and immunostained for MDMX (green) and MDM2 (red), while the nuclei were stained with Hoechst. Scale bar: 20 μm. * p < 0.05, **** p < 0.0001.
Murine Double Mutant 2 Mdm2 51541 Antibodies, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mutant+mdm2/pm36696776-134-10-20?v=Cell+Signaling+Technology+Inc
Average 95 stars, based on 1 article reviews
murine double mutant 2 mdm2 51541 antibodies - by Bioz Stars, 2026-08
95/100 stars
  Buy from Supplier
mutant mdm2  (Addgene inc)
92
Addgene inc mutant mdm2
A The frequency of p53 mutation in Diffuse Large B Cell lymphoma (DLBC) patients (DFCI, Nat Med, 2018 ), (Broad, PNAS, 2012), (BCGSC, Blood, 2013 ), (TCGA, PanCancer Atlas), (Duke, Cell, 2017) , ALL patients (St Jude, Nat Genet, 2016), (St Jude, Nat Genet, 2015) , and pediatric ALL patients (TARGET, 2018)—across public datasets in https://www.cbioportal.org . B U2OS cells were transfected with an empty or FLT4 expression plasmid along with a pg13 luciferase reporter vector or a luciferase reporter for p21 or MDM2 to determine p53 target genes activity. C U2OS cells were transfected with an empty or FLT4 expression vector for 24 h. The cells were then treated with 10 µg/mL of 5-FU for 6 h. The cell lysates were blotted for the indicated antibodies. D U2OS cells were transfected with different combinations of FLT4, MDM2, and MDMX plasmids along with pg13 luciferase reporter vector to determine endogenous p53 under genotoxic conditions with 5-FU. E HEK293T cells were transfected with various amounts of FLT4 expression plasmid for 24 h. The cell lysates were blotted for the indicated antibodies. F HEK293T cells were transfected with a combination of FLT4, MDMX and MDM2 expression plasmids for 24 h. The cell lysates were blotted for the indicated antibodies (LE low exposure, HE high exposure). G U2OS cells were transfected with a combination of FLT4, MDMX or MDM2 expression plasmids for 24 h. The cell lysates were blotted for the indicated antibodies. H U2OS cells were transfected with a combination of FLT4, MDMX, wild-type MDM2 or mutant MDM2 <t>C464A</t> expression plasmids for 24 h. The cell lysates were blotted for the indicated antibodies. I U2OS cells were transfected with a combination of FLT4, MDMX, and MDM2 expression plasmids and immunostained for MDMX (green) and MDM2 (red), while the nuclei were stained with Hoechst. Scale bar: 20 μm. * p < 0.05, **** p < 0.0001.
Mutant Mdm2, supplied by Addgene inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mutant+mdm2/pm30910997-276-6-13?v=Addgene+inc
Average 92 stars, based on 1 article reviews
mutant mdm2 - by Bioz Stars, 2026-08
92/100 stars
  Buy from Supplier

Image Search Results


A The frequency of p53 mutation in Diffuse Large B Cell lymphoma (DLBC) patients (DFCI, Nat Med, 2018 ), (Broad, PNAS, 2012), (BCGSC, Blood, 2013 ), (TCGA, PanCancer Atlas), (Duke, Cell, 2017) , ALL patients (St Jude, Nat Genet, 2016), (St Jude, Nat Genet, 2015) , and pediatric ALL patients (TARGET, 2018)—across public datasets in https://www.cbioportal.org . B U2OS cells were transfected with an empty or FLT4 expression plasmid along with a pg13 luciferase reporter vector or a luciferase reporter for p21 or MDM2 to determine p53 target genes activity. C U2OS cells were transfected with an empty or FLT4 expression vector for 24 h. The cells were then treated with 10 µg/mL of 5-FU for 6 h. The cell lysates were blotted for the indicated antibodies. D U2OS cells were transfected with different combinations of FLT4, MDM2, and MDMX plasmids along with pg13 luciferase reporter vector to determine endogenous p53 under genotoxic conditions with 5-FU. E HEK293T cells were transfected with various amounts of FLT4 expression plasmid for 24 h. The cell lysates were blotted for the indicated antibodies. F HEK293T cells were transfected with a combination of FLT4, MDMX and MDM2 expression plasmids for 24 h. The cell lysates were blotted for the indicated antibodies (LE low exposure, HE high exposure). G U2OS cells were transfected with a combination of FLT4, MDMX or MDM2 expression plasmids for 24 h. The cell lysates were blotted for the indicated antibodies. H U2OS cells were transfected with a combination of FLT4, MDMX, wild-type MDM2 or mutant MDM2 C464A expression plasmids for 24 h. The cell lysates were blotted for the indicated antibodies. I U2OS cells were transfected with a combination of FLT4, MDMX, and MDM2 expression plasmids and immunostained for MDMX (green) and MDM2 (red), while the nuclei were stained with Hoechst. Scale bar: 20 μm. * p < 0.05, **** p < 0.0001.

Journal: Oncogenesis

Article Title: FLT4 activation promotes acute lymphoid leukemia survival through stabilization of MDM2/MDMX and inactivation of p53

doi: 10.1038/s41389-025-00552-7

Figure Lengend Snippet: A The frequency of p53 mutation in Diffuse Large B Cell lymphoma (DLBC) patients (DFCI, Nat Med, 2018 ), (Broad, PNAS, 2012), (BCGSC, Blood, 2013 ), (TCGA, PanCancer Atlas), (Duke, Cell, 2017) , ALL patients (St Jude, Nat Genet, 2016), (St Jude, Nat Genet, 2015) , and pediatric ALL patients (TARGET, 2018)—across public datasets in https://www.cbioportal.org . B U2OS cells were transfected with an empty or FLT4 expression plasmid along with a pg13 luciferase reporter vector or a luciferase reporter for p21 or MDM2 to determine p53 target genes activity. C U2OS cells were transfected with an empty or FLT4 expression vector for 24 h. The cells were then treated with 10 µg/mL of 5-FU for 6 h. The cell lysates were blotted for the indicated antibodies. D U2OS cells were transfected with different combinations of FLT4, MDM2, and MDMX plasmids along with pg13 luciferase reporter vector to determine endogenous p53 under genotoxic conditions with 5-FU. E HEK293T cells were transfected with various amounts of FLT4 expression plasmid for 24 h. The cell lysates were blotted for the indicated antibodies. F HEK293T cells were transfected with a combination of FLT4, MDMX and MDM2 expression plasmids for 24 h. The cell lysates were blotted for the indicated antibodies (LE low exposure, HE high exposure). G U2OS cells were transfected with a combination of FLT4, MDMX or MDM2 expression plasmids for 24 h. The cell lysates were blotted for the indicated antibodies. H U2OS cells were transfected with a combination of FLT4, MDMX, wild-type MDM2 or mutant MDM2 C464A expression plasmids for 24 h. The cell lysates were blotted for the indicated antibodies. I U2OS cells were transfected with a combination of FLT4, MDMX, and MDM2 expression plasmids and immunostained for MDMX (green) and MDM2 (red), while the nuclei were stained with Hoechst. Scale bar: 20 μm. * p < 0.05, **** p < 0.0001.

Article Snippet: Expression plasmids, including pCMV-Myc-MDM2, pCMV-MDM2 C464A mutant, pcDNA3-FLT4, and pcDNA3-Flag-MDMX, were obtained from Addgene (#16441, #12086, #119230, and previously described [ ], respectively).

Techniques: Mutagenesis, Transfection, Expressing, Plasmid Preparation, Luciferase, Activity Assay, Staining